impact factor
logo
 

Full Papers

 

Factors influencing the EULAR Sjögren’s Syndrome Patient Reported Index in primary Sjögren’s syndrome


1, 2, 3

 

  1. Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
  2. Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
  3. Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico. gabyhm@yahoo.com

CER14627
Full Papers

purchase article

PMID: 34128801 [PubMed]

Received: 13/03/2021
Accepted : 07/06/2021
In Press: 14/06/2021

Abstract

OBJECTIVES:
The ESSPRI is a validated tool for measuring pain, fatigue and dryness in primary Sjögren’s syndrome (pSS). We evaluated its association with disease and non-disease related variables, and its variation though the follow-up.
METHODS:
We included 130 pSS patients who were interviewed to register demographics, schooling, smoking, menopause, body mass index (BMI), disease duration, use of hormonal replacement, associated sicca drugs, prednisone, immunosuppressors/antimalarials, comorbidities such as diabetes mellitus, hypothyroidism, depression, fibromyalgia and scored the Charlson comorbidity index. We assessed the non-stimulated whole salivary flow (NSWSF), Schirmer-I test, ESSDAI and ESSPRI scores. In a subset of patients, we scored a second ESSPRI.
RESULTS:
Most patients were women, mean age 57 years and median disease duration 9.3 years. The median ESSPRI score was 6 (fatigue 6, pain 4, dryness 8). Eighty patients (61.5%) had an ESSPRI ≥5 points and were characterized by a higher prevalence of depression (OR 3.7, 95% 1.2-11.3) and lower NSWSF (OR 0.59, 95% CI 0.36-0.97). Among 62 patients with a second ESSPRI (median time 25 months), 44 (70%) experienced a decrement/increment ≥1 in the ESSPRI (16 were decrement). We did not find any of the studied variables associated with this variation, also including change in prednisone or immunosuppressors.
CONCLUSIONS:
An ESSPRI ≥5 (unsatisfactory symptom state) was associated with low NSWSF and depression. Most of the patients experienced a clinically significant ESSPRI variation (increment or decrement), nevertheless, we were not able to identify any variable associated with this change. Further studies would be helpful to understand the underlying causes.

Rheumatology Article